| Literature DB >> 24280356 |
Meghan L Verschoor1, Chris P Verschoor, Gurmit Singh.
Abstract
BACKGROUND: The Ets-1 proto-oncogene is frequently upregulated in cancer cells, with known involvement in cancer angiogenesis, metastasis, and more recently energy metabolism. In this study we have performed various bioinformatic analyses on existing microarray data to further clarify the role of Ets-1 in ovarian cancer, and validated these results with functional assays.Entities:
Year: 2013 PMID: 24280356 PMCID: PMC4178218 DOI: 10.1186/2049-3002-1-17
Source DB: PubMed Journal: Cancer Metab ISSN: 2049-3002
Figure 1Global functional interaction network. Reactome FI was used to create a functional interaction network, which is divided into modules as defined by node coloring, and further delineated by functional pathway enrichments into outlined, color-coded groups. Major associations among the curated and predicted interactions included cell cycle regulatory, RNA slicing, metabolism, WNT signaling, and insulin-related pathways (FDR <0.01). Network was generated in Cytoscape.
Functional annotation clustering of genes associated with Ets-1 overexpression
| 1 | INTERPRO | IPR010257:Fatty acid desaturase, type 1, N-terminal | 0.00 | 15.75 |
| GOTERM_MF_ALL | GO:0016717~Oxidoreductase activity (O or H2O as acceptor) | 0.00 | 13.63 | |
| INTERPRO | IPR005804:Fatty acid desaturase, type 1 | 0.00 | 13.13 | |
| 2 | PANTHER_FAMILY | PTHR19353:Fatty acid desaturase 2 | 0.001 | 20.40 |
| INTERPRO | IPR012171:Fatty acid/sphingolipid desaturase | 0.001 | 19.69 | |
| PIR_SUPERFAMILY | PIRSF015921:Fatty acid desaturase/sphingolipid desaturase | 0.001 | 19.22 | |
| GOTERM_BP_ALL | GO:0006636~Unsaturated fatty acid biosynthetic process | 0.001 | 14.89 | |
| GOTERM_BP_ALL | GO:0033559~Unsaturated fatty acid metabolic process | 0.001 | 14.89 | |
| 3 | KEGG_REACTION | R05053:D-aspartate + D-4-hydroxy-2-oxoglutarate <=> Oxaloacetate + L-erythro-4-hydroxyglutamate | 0.001 | 2.78 |
| KEGG_COMPOUND | C05947:L-erythro-4-hydroxyglutamate | 0.001 | 2.76 | |
| KEGG_COMPOUND | C05946:D-4-hydroxy-2-oxoglutarate | 0.001 | 2.76 | |
| KEGG_COMPOUND | C00036:Oxaloacetate | 0.001 | 2.76 | |
| KEGG_COMPOUND | C00402:D-aspartate | 0.001 | 2.76 | |
| 4 | GOTERM_MF_ALL | GO:0047115~trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity | 0.001 | 20.44 |
| EC_NUMBER | 1.1.1.213 | 0.001 | 16.92 | |
| EC_NUMBER | 14.3.1.20 | 0.001 | 16.92 | |
| 5 | PIR_SUPERFAMILY | PIRSF001191:Matrix metalloproteinase, stromelysin type | 0.01 | 5.34 |
| INTERPRO | IPR002477:Peptidoglycan binding-like | 0.02 | 4.92 | |
| PANTHER_FAMILY | PTHR10201:Matrix metalloproteinase | 0.02 | 4.43 | |
| INTERPRO | IPR000585:Hemopexin | 0.03 | 4.10 | |
| INTERPRO | IPR006026:Peptidase, metallopeptidases | 0.04 | 3.79 | |
| GOTERM_BP_ALL | GO:0000270~Peptidoglycan metabolic process | 0.05 | 3.54 | |
| 6 | INTERPRO | IPR001314:Peptidase S1A, chymotrypsin | 0.02 | 2.28 |
| INTERPRO | IPR001254:Peptidase S1 and S6, chymotrypsin/Hap | 0.04 | 2.10 | |
| PANTHER_FAMILY | PTHR19355:Serine protease-related | 0.04 | 2.10 | |
| 7 | INTERPRO | IPR001039:MHC class I, alpha chain, alpha1 and alpha 2 | 0.02 | 4.69 |
| PANTHER_FAMILY | PTHR16675:MHC class 1-related | 0.03 | 4.08 | |
| INTERPRO | IPR011161:MHC classi-like antigen recognition | 0.04 | 9.94 | |
| GOTERM_CC_ALL | GO:0042612~MHC class I protein complex | 0.04 | 3.91 | |
| 8 | INTERPRO | IPR010579:MHC class I, alpha chain, C-terminal | 0.01 | 14.77 |
| PFAM | PF06623:MHC_I_C | 0.01 | 14.63 |
Figure 2Enrichment map of gene set enrichment analysis. The map shows enriched gene sets in 2008 versus 2008-Ets1 ovarian cancer cells clustered by MCODE to generate sub-networks of the interrelated gene sets. Red nodes indicate enrichment (upregulation) in 2008 cells, green nodes represent enrichment (upregulation) in 2008-Ets1 cells. Node size is representative of the number of enriched genes in the gene set. The largest cluster includes the signaling pathways of ERK5, MAPK, EGF, PDGF, MET and GPCR. Notably, clusters with gene sets involved in mitochondrial metabolism and fatty acid metabolic processes were also identified. Network was generated in Cytoscape.
Figure 3Integrating various bioinformatic analyses. Venn diagram representing the overlapping enrichments from the various bioinformatic pathway analyses (Figures 1 and 2, Table 1) employed on the microarray expression data. The functional interaction network and ontological analyses both included enrichments in antigen presentation, and the ontological analysis shared oxidoreductase activity enrichment with the gene set enrichment analysis. All three analyses found enrichments in various metabolic pathways.
Figure 4Ets-1 regulated oxidative stress in ovarian cancer cells. (A) The protein expression of Ets1, GPX-1 and GPX-2 were examined via western blot, and normalized to Actin expression by densitometry analysis. Ets-1 overexpressing cells show 3.10-fold and 2.25-fold inductions in GPX-1 and GPX-2 protein levels, respectively. (B) Intracellular ROS levels were measured using the fluorescent CM2-H2DCFDA reagent in ovarian cancer cells. 2008-Ets1 cells contained lower ROS levels than 2008 cells (1233.99 AFU and 1872.73 AFU, respectively). (C) The activity of glutathione peroxidase enzymes was measured using a colorimetric assay, where Ets-1 overexpressing cells were observed to have significantly higher activity than parental cells (7725.66 U/mL/mg and 3944.22 U/mL/mg, respectively).
Figure 5Breast cancer cell model of Ets-1 expression knockdown. MDA-MB-231 breast cancer cells were stably depleted of Ets-1 expression via targeted shRNA knockdown. (A) The Ets-1 knockdown cell line MDA-Ets1KD expresses Ets-1 protein at 22.7% of parental protein levels in MDA-MB-231 cells. (B) Real-time qRT-PCR of the breast cancer Ets-1 expression model. The gene expression of PDHA, CYC1, NDUFAB1 and SDHB were increased in MDA-Ets1KD cells, whereas the expression of G6PD was downregulated.
Figure 6Effect of Ets-1 knockdown on breast cancer cell metabolism. (A) MDA-MB-231 and MDA-Ets1KD cells were treated with various amounts of the glycolytic inhibitor 2-DG, and representative growth curves were generated for each cell line. The 2-DG IC50 was greater in MDA-Ets1KD cells, with an IC50 of 3.94 mM compared to an IC50 of 2.03 mM for MDA-MB-231 cells. (B) Basal oxygen consumption was measured using high-resolution respirometry, and MDA-Est1KD cells were observed to consume significantly more oxygen (41.80 pmol/106 cells/s) than parental MDA-MB-231 cells (21.07 pmol/106 cells/s).